Nov
19
Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, […]
Read More